吉非替尼对老年晚期EGFR突变型非小细胞肺癌的疗效及对MMP-9、TIMP-1水平的影响  

Efficacy of Gefitinib in the Treatment of Ederly Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer and Its Effect on MMP-9,TIMP-1 Levels and Prognosis

作　　者：赵景景 谭于飞 李玲 赵兵 ZHAO Jingjing;TAN Yufei;LI Ling(Zhumadian Central Hospital,Zhumadian,463000)

机构地区：[1]河南省驻马店市中心医院,463000

出　　处：《实用癌症杂志》2023年第1期156-159,共4页The Practical Journal of Cancer

摘　　要：目的研究吉非替尼治疗老年晚期EGFR突变型NSCLC的效果及对MMP-9、TIMP-1水平和预后的影响。方法选择110例老年晚期EGFR突变型NSCLC患者进行研究,根据随机数表法,把患者均分为对照组和观察组,各55例。对照组给予常规治疗,观察组另加予吉非替尼治疗。比较两组的治疗效果,治疗前后的MMP-9、TIMP-1水平和CYFRA21-1、CEA水平,生存情况以及不良反应。结果观察组总有效率(92.72%)显著高于对照组(78.18%,P<0.05)。治疗前两组MMP-9、TIMP-1水平差异均无统计学意义(P>0.05);治疗后观察组MMP-9、TIMP-1水平均显著低于对照组(P<0.05)。治疗前两组CYFRA21-1、CEA水平差异均无统计学意义(P>0.05);治疗后观察组CYFRA21-1、CEA水平均显著低于对照组(P<0.05)。观察组半年、1年生存率显著高于对照组且复发转移率显著低于对照组(P<0.05)。两组不良反应无统计学意义(P>0.05)。结论老年晚期EGFR突变型NSCLC患者应用吉非替尼治疗的效果显著,能够明显降低其MMP-9、TIMP-1水平,并改善预后。Objective To study the effect of gefitinib in the treatment of elderly patients with advanced EGFR mutant NSCLC and its effect on the levels of MMP-9,TIMP-1 and prognosis.Methods 110 elderly patients with late EGFR mutant NSCLC were selected for the study.According to the method of random number table,the patients were divided into the control group and the observation group,55 patients in each group.The control group was given routine treatment,and the observation group was treated with gefitinib.The therapeutic effects,MMP-9,TIMP-1 levels and adverse reactions of the 2 groups were compared before and after treatment.Results The total effective rate of the observation group(92.72%)was significantly higher than that of the control group(78.18%,P<0.05).Before treatment,there was no significant difference in the levels of MMP-9 and TIMP-1 between the 2 groups(P>0.05);after treatment,the levels of MMP-9 and TIMP-1 in the observation group were significantly lower than those in the control group(P<0.05).Before treatment,there was no significant difference in the levels of CYFRA21-1 and CEA between the two groups(P>0.05);after treatment,the levels of CYFRA21-1 and CEA in the observation group were significantly lower than those in the control group(P<0.05).6-month and 1-year survival rates in the observation group were significantly higher than those in the control group,and the recurrence and metastasis rates were significantly lower than those in the control group(P<0.05).There was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion Gefitinib can significantly reduce the levels of MMP-9 and TIMP-1 and improve the prognosis in elderly patients with advanced EGFR mutant NSCLC.

关 键 词：突变型非小细胞肺癌 老年 吉非替尼 效果 预后 

分 类 号：R734.2[医药卫生—肿瘤]